Literature DB >> 25568989

Increased cervical cancer risk associated with screening at longer intervals.

Walter Kinney1, Thomas C Wright, Helen E Dinkelspiel, Mark DeFrancesco, J Thomas Cox, Warner Huh.   

Abstract

The 2012 national recommendations for cervical cancer screening will produce a lower level of cervical cancer protection than previously afforded by annual cytology or 3-year cotesting. After a single negative cotest result, the risk of cervical cancer is twice as large at 5 years as it is at 3 years. Modeling published since the 2012 guidelines were drafted indicates that extending the cotesting screening interval from 3 to 5 years at ages 30-64 years will result in an additional 1 woman in 369 compliant with screening receiving a cervical cancer diagnosis during her lifetime, and an additional 1 in 1,639 dying of cervical cancer. The authors believe that a significant number of patients and providers would not choose to accept these additional risks if they understood them, despite the recognition of potential harms associated with more intensive screening.

Entities:  

Mesh:

Year:  2015        PMID: 25568989     DOI: 10.1097/AOG.0000000000000632

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  16 in total

1.  A Suggested Approach to Simplify and Improve Cervical Screening in the United States.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

2.  Gynaecological cancer: New standard of care—HPV testing for cervical cancer screening.

Authors:  Philip E Castle
Journal:  Nat Rev Clin Oncol       Date:  2015-02-24       Impact factor: 66.675

3.  Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Authors:  Mark Schiffman; Walter K Kinney; Li C Cheung; Julia C Gage; Barbara Fetterman; Nancy E Poitras; Thomas S Lorey; Nicolas Wentzensen; Brian Befano; John Schussler; Hormuzd A Katki; Philip E Castle
Journal:  J Natl Cancer Inst       Date:  2018-05-01       Impact factor: 13.506

4.  Protection against cervical cancer versus decreasing harms from screening - What would U.S. patients and clinicians prefer, and do their preferences matter?

Authors:  Walter K Kinney; Warner K Huh
Journal:  Prev Med       Date:  2017-02-06       Impact factor: 4.018

5.  Point-Counterpoint: Cervical Cancer Screening Should Be Done by Primary Human Papillomavirus Testing with Genotyping and Reflex Cytology for Women over the Age of 25 Years.

Authors:  Mark H Stoler; R Marshall Austin; Chengquan Zhao
Journal:  J Clin Microbiol       Date:  2015-05-06       Impact factor: 5.948

6.  Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.

Authors:  Ming Guo; Abha Khanna; Jianping Wang; Marilyn A Dawlett; Teresa L Kologinczak; Genevieve R Lyons; Roland L Bassett; Nour Sneige; Yun Gong; Therese B Bevers
Journal:  Cancer Cytopathol       Date:  2017-05-12       Impact factor: 5.284

7.  Why does cervical cancer occur in a state-of-the-art screening program?

Authors:  Philip E Castle; Walter K Kinney; Li C Cheung; Julia C Gage; Barbara Fetterman; Nancy E Poitras; Thomas S Lorey; Nicolas Wentzensen; Brian Befano; John Schussler; Hormuzd A Katki; Mark Schiffman
Journal:  Gynecol Oncol       Date:  2017-06-10       Impact factor: 5.482

8.  The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: Reduced cervical cancer risk and decreased yield of precancer per screen.

Authors:  Michelle I Silver; Mark Schiffman; Barbara Fetterman; Nancy E Poitras; Julia C Gage; Nicolas Wentzensen; Thomas Lorey; Walter K Kinney; Philip E Castle
Journal:  Cancer       Date:  2016-09-22       Impact factor: 6.860

9.  How Colposcopy Misses Invasive Cervical Cancer: A Case Report from the IMPROVE-COLPO Study.

Authors:  Jeff Livingston; Emmanouil Papagiannakis
Journal:  Case Rep Obstet Gynecol       Date:  2016-10-18

10.  The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.

Authors:  Juan C Felix; Michael J Lacey; Jeffrey D Miller; Gregory M Lenhart; Mark Spitzer; Rucha Kulkarni
Journal:  J Womens Health (Larchmt)       Date:  2016-03-29       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.